Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hépargitol is a gastrointestinal medication developed by Laboratoires Élerté, formulated as an oral solution containing arginine hydrochloride and sorbitol. It is primarily used for the symptomatic treatment of dyspeptic disorders, such as slow digestion, bloating, and abdominal discomfort. Arginine is an amino acid that serves as a key intermediate in the urea cycle, facilitating the detoxification of ammonia in the liver. Sorbitol is a polyol that acts as an osmotic laxative and stimulates the release of cholecystokinin (CCK) from the intestinal mucosa. The release of CCK promotes gallbladder contraction and the secretion of pancreatic enzymes, thereby improving bile flow and overall digestive function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine + sorbitol.